Canada markets close in 5 hours 37 minutes
  • S&P/TSX

    21,119.64
    -6.26 (-0.03%)
     
  • S&P 500

    4,639.76
    +45.14 (+0.98%)
     
  • DOW

    35,009.89
    +110.55 (+0.32%)
     
  • CAD/USD

    0.7832
    +0.0012 (+0.15%)
     
  • CRUDE OIL

    71.28
    +3.13 (+4.59%)
     
  • BTC-CAD

    72,838.69
    +3,144.68 (+4.51%)
     
  • CMC Crypto 200

    1,430.42
    +1.48 (+0.10%)
     
  • GOLD FUTURES

    1,790.00
    +1.90 (+0.11%)
     
  • RUSSELL 2000

    2,258.87
    +12.94 (+0.58%)
     
  • 10-Yr Bond

    1.5380
    +0.0560 (+3.78%)
     
  • NASDAQ

    15,709.30
    +217.64 (+1.40%)
     
  • VOLATILITY

    24.36
    -4.26 (-14.88%)
     
  • FTSE

    7,141.83
    +97.80 (+1.39%)
     
  • NIKKEI 225

    28,283.92
    -467.70 (-1.63%)
     
  • CAD/EUR

    0.6945
    +0.0040 (+0.58%)
     

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Jeff Dekker, Chief Financial Officer, will present at the Q3 Virtual Investor Summit being held August 17-18, 2021.

ARCA is scheduled to present on Wednesday, August 18, 2021 at 1:15 PM ET. Management will be available for one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at: https://zoom.us/webinar/register/WN_ERJdeAK7QtKvTBMwC5gpcg .

About ARCA biopharma
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2b clinical testing. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.

Investor & Media Contact:
Derek Cole
720.940.2163
derek.cole@arcabio.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting